Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04145700 · ClinicalTrials.gov registry record · Phase 1
CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Synovial Sarcoma
A Phase 1 study, sponsored by Eli Lilly and Company.
- Terminated
- Registry status
- Phase 1
- Development phase
- 23
- Enrollment target
NCT04145700 is a Phase 1 study that was terminated before completion, run by Eli Lilly and Company. The registered enrollment target is 23 participants.
The verdict
NCT04145700, a Phase 1 study, was terminated before completion, sponsored by Eli Lilly and Company.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 23 participants
- Enrollment target
Study Summary
This study is being conducted to test the safety and efficacy of ramucirumab in combination with other chemotherapy in the treatment of relapsed, recurrent, or refractory synovial sarcoma (SS) in children and young adults. This trial is part of the CAMPFIRE master protocol (NCT05999994) which is a platform to accelerate the development of new treatments for pediatric and young adult participants with cancer. Your participation in this trial could last 12 months or longer, depending on how you and your tumor respond.
Interventions
- DRUG Docetaxel
- DRUG Gemcitabine
- DRUG Ramucirumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2020-03-04 |
| Est. Completion | 2023-02-23 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04145700
The ClinicalTrials.gov registry entry for NCT04145700 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Docetaxel is the first listed.
NCT04145700 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04145700 about?
NCT04145700 is a clinical study titled "CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Synovial Sarcoma". This study is being conducted to test the safety and efficacy of ramucirumab in combination with other chemotherapy in the treatment of relapsed, recurrent, or refractory synovial sarcoma (SS) in children and young adults. This trial is part of the CAMPFIRE master protocol (NCT05999994) which is a p...
What is the current status of trial NCT04145700?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 23 participants. The study started on 2020-03-04. Estimated completion is 2023-02-23.
What interventions are being tested in trial NCT04145700?
The interventions under investigation include: Docetaxel (DRUG), Gemcitabine (DRUG), Ramucirumab (DRUG).
Who is sponsoring clinical trial NCT04145700?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.